TMPRSS4 as an emerging potential poor prognostic factor for solid tumors: A systematic review and meta-analysis

Ping Zeng, Peng Zhang, Li-Na Zhou, Min Tang, Yi-Xin Shen, Jun Jin, Ya-Qun Zhu and Min-Bin Chen _

PDF  |  HTML  |  How to cite

Oncotarget. 2016; 7:76327-76336. https://doi.org/10.18632/oncotarget.10153

Metrics: PDF 2502 views  |   HTML 2092 views  |   ?  


Ping Zeng1,*, Peng Zhang2,*, Li-Na Zhou1,*, Min Tang1, Yi-Xin Shen2, Jun Jin1, Ya-Qun Zhu3 and Min-Bin Chen1

1 Department of Radiotherapy and Oncology, Kunshan First People’s Hospital Affiliated to Jiangsu University, Kunshan, Jiangsu Province, China

2 Department of Orthopedics, the Second Affiliated Hospital of Soochow University, Suzhou, China

3 Department of Radiotherapy and Oncology, The Second Affiliated Hospital of Soochow University, Institute of Radiotherapy & Oncology, Soochow University, Suzhou, China

* These authors have contributed equally to this work and should be considered co-first authors

Correspondence to:

Min-Bin Chen, email:

Keywords: TMPRSS4, tumor, prognosis, overall survival, time to tumor progression

Received: April 10, 2016 Accepted: June 02, 2016 Published: June 17, 2016


Recent studies have investigated the potential prognostic value of the transmembrane protease serine 4 (TMPRSS4) in various solid tumors. Yet, the results are inconclusive. Here, we performed this meta-analysis to clarify this issue. Relevant articles were identified by searching PubMed, Web of Science and Embase databases. The primary outcome endpoints were patients’ overall survival (OS) and time to tumor progression (TTP). Twelve studies involving 1,955 participants were included. We showed that high TMPRSS4 expression in tumor tissues was significantly associated with patients’ poor OS (pooled HR = 2.981, 95% CI = 2.296-3.869, P < 0.001) and short TTP (pooled HR = 2.456, 95% CI = 1.744-3.458, P < 0.001). A subgroup analysis revealed that the association between TMPRSS4 and the outcome endpoints (OS or TTP) was also significant within China region. We conclude that TMPRSS4 overexpression in solid tumors is associated with patients’ poor prognosis. TMPRSS4 could be a valuable prognosis biomarker or a promising therapeutic target of solid tumor.

Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 10153